United states : GTx To Provide Update On Pending Toremifene New Drug Application.Byline: pinto03 GTx Inc. (GTXI: News ), which is awaiting FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval for toremifene 80 mg, an investigational drug for the prevention of bone fractures in men with prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. on androgen deprivation therapy, will host a conference call and webcast on Monday, November 2, to provide an update on the drug's status. The FDA was to make a decision on the drug on October 30. Androgen deprivation therapy, or ADT (Asynchronous Data Transfer) A transmission technique used in ISDN PBXs that dynamically allocates bandwidth. See also abstract data type. ADT - abstract data type , the main treatment for advanced prostate cancer, works by reducing testosterone levels by up to 95%. Testosterone is a primary growth factor of prostate cancer. However ADT also substantially depletes estrogen levels, the hormone responsible for bone quality and strength. Depletion of estrogen can result in serious side effects Side effects Effects of a proposed project on other parts of the firm. , including a high risk of bone fractures, adverse lipid changes and increased risk of cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease , as well as common symptomatic side effects such as growth of breast tissue often accompanied by tenderness and pain, and hot flashes. GTx already markets toremifene 60 mg under the brand name Fareston for the treatment of advanced breast cancer in more than 60 countries including the U.S. Copyright : Euclid Infotech Pvt. Ltd. Provided by Syndigate.info an Albawaba.com company |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion